Sanofi's Sarclisa Scores In Myeloma But Is Still In Darzalex’s Shadow
Best PFS In Second Line Setting
Executive Summary
The French company believes it has the best-in-class CD38 antibody with new PFS data, but Johnson & Johnson and Genmab’s Darzalex looks set to retain its advantage in multiple myeloma.
You may also be interested in...
Sanofi Challenges J&J’s Darzalex With Blackstone Pact For SC Sarclisa
The French major has entered a risk-sharing collaboration with Blackstone focused on a new formulation of multiple myeloma drug Sarclisa, which could help it take on market leader Darzalex.
Sanofi Makes Case For Frontline Use Of Myeloma Drug Sarclisa
Sarclisa, Sanofi's first in-house cancer drug to be approved since 2010, is making slow if steady progress on the sales front but remains way behind J&J's multiple myeloma behemoth Darzalex. Still, the company has been touting its case to be the anti-CD38 of choice at the ASH meeting.
Encouraging Biomarker Data Lift UniQure’s Huntington’s Disease Hopes
Hopes rise as first four evaluable patients experienced no serious adverse events, and a sustained decline in level of key Huntington’s disease protein with the novel gene therapy product.